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Abstract
Background: The aim of this paper is to evaluate the effect of antipsychotics for the treatment of
schizophrenia in a community based study on sexual function and prolactin levels comparing the
use of aripiprazole and standard of care (SOC), which was a limited choice of three widely used
and available antipsychotics (olanzapine, quetiapine or risperidone) (The Schizophrenia Trial of
Aripiprazole [STAR] study [NCT00237913]).
Method: This open-label, 26-week, multi-centre, randomised study compared aripiprazole to
SOC (olanzapine, quetiapine or risperidone) in patients with schizophrenia (DSM-IV-TR criteria).
The primary effectiveness variable was the mean total score of the Investigator Assessment
Questionnaire (IAQ) at Week 26. The outcome research variables included the Arizona Sexual
Experience scale (ASEX). This along with the data collected on serum prolactin levels at week 4,
8, 12, 18 and 26 will be the focus of this paper.
Results: A total of 555 patients were randomised to receive aripiprazole (n = 284) or SOC (n =
271). Both treatment groups experienced improvements in sexual function from baseline ASEX
assessments. However at 8 weeks the aripiprazole treatment group reported significantly greater
improvement compared with the SOC group (p = 0.007; OC). Although baseline mean serum
prolactin levels were similar in the two treatment groups (43.4 mg/dL in the aripiprazole group and
42.3 mg/dL in the SOC group, p = NS) at Week 26 OC, mean decreases in serum prolactin were
34.2 mg/dL in the aripiprazole group, compared with 13.3 mg/dL in the SOC group (p < 0.001).
Conclusion: The study findings suggest that aripiprazole has the potential to reduce sexual
dysfunction, which in turn might improve patient compliance.
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Background
All antipsychotic medications have the potential to cause
hyperprolactinaemia, as the inhibition of dopamine
release effectively removes the negative feedback loop for
prolactin secretion from the anterior pituitary gland [1].
Elevated serum prolactin levels have been shown to have
profound effects on reproductive health and sexual func-
tion, including hypogonadism, decreased libido in both
sexes, amenorrhoea and infertility in women and low
sperm count and reduced muscle mass in men [2]. In
addition, there is evidence to suggest a link between
hyperprolactinaemia and reduced bone mineral density –
a study of women with hyperprolactinaemia showed a
15–30% reduction in bone mineral density compared
with healthy women [3]. There is also a suspected link
between elevated plasma prolactin levels and breast can-
cer, although the causal relationship in this link remains
to be established [1].
Although psychotic illness can be associated with sexual
problems there have been considerable reports in the lit-
erature of sexual dysfunction related to antipsychotic use
being a significant issue of patients, which may have a
negative impact on the patient's quality of life and adher-
ence to treatment [4,5]. Clinical studies have demon-
strated that with the exception of risperidone, atypical
antipsychotics have significantly less impact on serum
prolactin compared with conventional antipsychotics [6-
10], and are also less likely to cause sexual dysfunction
[11-13]. In addition Gopalakrishnan et al [5] has shown
that it is possible to successfully treat antipsychotic sexual
dysfunction with sildenafil including patients exhibiting
raised prolactin levels. In this study 74% (23 patients) of
the sildenafil treatment group felt that in future they
would use this treatment compared to 26% of the placebo
group. Whilst short-term clinical studies with aripiprazole
have shown comparable serum prolactin levels to placebo
[14], the effects of aripiprazole on serum prolactin and
sexual function over a longer period of time have yet to be
investigated.
The Schizophrenia Trial of Aripiprazole (STAR) study is a
naturalistic effectiveness study conducted with the aim of
providing critical information on the relationships
between the condition, the medication, and the patients
in their everyday care setting. Following an initial review
of atypical antipsychotics in 2002, the UK National Insti-
tute of Health and Clinical Excellence (NICE) found a lack
of 'real-world' data such as patient-reported outcomes,
patient preferences, and treatment regimens based on the
clinician's judgment [15]. For subsequent reviews, NICE
has acknowledged that whilst randomised clinical trials
are of restricted applicability to the general patient popu-
lation due to their limited duration and number of varia-
bles measured, naturalistic studies such as STAR allow
evaluations of treatment effectiveness using less selective
patient criteria and a wider spectrum of effectiveness vari-
ables (such as safety, tolerability, symptom relief or wors-
ening, patient preference for medication, quality of life,
and cost-effectiveness) [16,17].
The primary objective of the STAR study was to evaluate
the effectiveness of a 26-week treatment of aripiprazole
versus standard of care (SOC), which was a limited choice
of three widely used and available antipsychotics (olanza-
pine, quetiapine or risperidone), in patients treated for
schizophrenia in a community health or hospital-based
outpatient setting. Outcomes research variables included
quality of life and sexual function as secondary outcomes,
and the safety evaluation included monitoring of serum
prolactin levels. This paper will discuss specifically the
findings with respect to sexual function in light of the
serum prolactin analysis.
Methods
Patients
Patients at 98 centres in 12 countries throughout Europe
were enrolled in the study between July 2004 and June
2005. The study protocol complied with the Declaration
of Helsinki and Good Clinical Practices (GCP) guidelines
and was approved by the Institutional Review Board
(IRB)/Independent Ethics Committee (IEC) at the indi-
vidual study centres. Prior to study enrolment, informed
written consent was obtained from all patients.
Eligible for inclusion in the study were male and female
patients aged 18 to 65 years with a diagnosis of schizo-
phrenia (DSM-IV-TR criteria) treated within a community
mental health or hospital-based outpatient centre, for
whom a change of antipsychotic medication was indi-
cated due to lack of tolerability and/or symptom control
as judged by the clinician.
Key exclusion criteria included acute psychotic symptoms
requiring hospitalisation, risk of committing suicide, a
diagnosis of schizoaffective disorder, bipolar disorder,
depression with psychotic symptoms, or organic brain
syndrome. Patients were also excluded if they were con-
sidered treatment resistant, had had a significant psycho-
active substance use disorder within 3 months prior to
screening, or had any history of neuroleptic malignant
syndrome, epilepsy, seizures, abnormal electroencephalo-
gram, severe head injury, or stroke.
Study design
The design and methodology of the STAR study have been
presented in detail elsewhere; hence only a summary will
be provided here [18].BMC Psychiatry 2008, 8:95 http://www.biomedcentral.com/1471-244X/8/95
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The STAR study was designed as a multi-centre, ran-
domised, naturalistic, open-label study to compare arip-
iprazole treatment with SOC treatment (limited to a
choice of olanzapine, quetiapine or risperidone). Eligible
patients were randomised to receive treatment with arip-
iprazole or SOC for a period of 26 weeks. Patients ran-
domised to the SOC group received one of three selected
atypical antipsychotics: olanzapine, quetiapine, or risperi-
done, based on the investigator's/clinician's judgment as
to the optimal treatment for the individual patient and
taking into account the patients' previous response to
antipsychotic medication.
A cross-titration period of up to 14 days was permitted fol-
lowing the randomisation, with complete discontinua-
tion of any pre-study antipsychotic medication by Day 15.
During the 26-week open-label treatment phase, study
visits occurred at Weeks 2, 4, 8, 12, 18 and 26 to assess the
effectiveness of study treatment.
Patients randomised to the aripiprazole group received a
starting dose of 15 mg/day followed by a daily dose of 10–
30 mg/day, as judged by the investigator, administered
orally once daily independent of meals. Patients ran-
domised to the SOC group received either olanzapine,
starting at 10 mg once daily followed by a daily dose of 5–
20 mg/day; quetiapine, starting with 50 mg/day on Day 1,
100 mg/day on Day 2, 200 mg/day on Day 3, and 300 mg/
day on Day 4, then followed by an individually titrated
dose of 800 mg/day maximum; risperidone, starting with
2 mg/day on Day 1, 4 mg/day on Day 2, then a daily dose
of 2–16 mg/day; or dosages according to the approved
local labelling for each of the three medications.
Benzodiazepines and anticholinergics were allowed dur-
ing the study if deemed necessary by the investigator.
Other psychotropic medications such as antidepressants
and mood stabilisers were allowed if the patient was
already receiving these medications when entering the
study. No additional antipsychotics were allowed during
the study.
Evaluations
Effectiveness assessments
Full details of the Investigator Assessment Questionnaire
(IAQ) and Clinical Global Impression (CGI) Improve-
ment (CGI-I) and Severity (CGI-S) assessments have been
published elsewhere [18]. Briefly, the clinical effectiveness
of the study treatments was assessed through the IAQ. The
primary effectiveness variable in the trial was the mean
total score of the 10-item IAQ at Week 26, last observation
carried forward (LOCF).
Secondary effectiveness variables included the CGI-I and
CGI-S scales. IAQ, CGI-I and CGI-S scores were obtained
at Weeks 2, 4, 8, 12, 18, and at the end of Week 26.
Outcomes research assessments
The STAR study outcomes research evaluation comprised
the following tools: the Preference of Medicine (POM)
questionnaire, the Quality of Life Scale (QLS), the Client
Socio-demographic and Service Receipt Inventory – Euro-
pean version (CSSRI-EU), EuroQoL-5D (EQ-5D), Impact
of Weight on Quality of Life (IWQoL-Lite), and the Ari-
zona Sexual Experience Scale (ASEX). This paper will
report and discuss the findings of the ASEX analysis; the
other analyses will be reported separately.
Arizona Sexual Experience Scale (ASEX)
The ASEX is a 5-item scale to assess sexual dysfunction
amongst psychiatric patients [19]. The ASEX rates sex
drive, arousal, vaginal lubrication/penile erection, ability
to reach orgasm, and satisfaction from orgasm. Male and
female patients are assessed separately. Possible Total
Score ranges from 5 to 30, with the higher score indicating
more patient sexual dysfunction. The scale could be either
self-administered or clinician-administered at the discre-
tion of the treating clinician. The scale is applicable to
patients regardless of the availability of a sexual partner.
The ASEX was administered at baseline and at Weeks 8,
18, with a final assessment at the end of Week 26 or at the
time of premature discontinuation.
Safety assessments
The safety variables of interest for this paper are the
change from baseline in serum prolactin levels through-
out the study, and the proportion of patients with poten-
tially clinically significant elevations in prolactin levels.
Prolactin serum levels were assessed by the Abbott AxSYM
system prolactin assay – a Microparticle Enzyme Immu-
noassay (MEIA) for the quantitative measurement of
serum prolactin. The normal range for this test was
defined as 1.6–18.8 mg/dL for men and 1.4–24.2 mg/dL
for women. The Statistical Analysis Plan for the STAR
study defines a clinically significant lab value for prolactin
as any value above the upper limit of normal. In addition
to serum prolactin, the safety analysis comprised the inci-
dence of adverse events (AEs), including treatment-emer-
gent AEs, AEs leading to discontinuation, treatment-
emergent serious AEs, and treatment-emergent EPS-
related AEs. Additional safety endpoints included the pro-
portion of subjects with potentially clinically relevant
vital signs/laboratory findings as defined by the Food and
Drug Administration Division of Neuropharmacological
Drug Products [20]BMC Psychiatry 2008, 8:95 http://www.biomedcentral.com/1471-244X/8/95
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Statistical procedures
Sample size and power
It was estimated that 556 patients would have to be ran-
domised to obtain 500 evaluable patients (250 on arip-
iprazole and 250 on SOC), assuming that 90% of the
randomised patients would be evaluable in the primary
endpoint. This sample size would yield 95% statistical
power with a true difference in the primary endpoint of 2.
This assumed a standard deviation of 6.2 and a 2-sided t-
test at the 0.05 level of significance. This sample size
would also allow for meaningful analysis of secondary
endpoints for which it is difficult to obtain reliable esti-
mates of variance, and for exploratory analysis to estimate
the effect size of aripiprazole relative to the individual
SOC items.
Data sets
The safety sample comprised all randomised patients who
took at least one dose of study medication. The effective-
ness sample included all patients in the safety sample who
had at least one post-baseline effectiveness evaluation
(IAQ or CGI). The outcome research sample, which
included assessments of quality of life and medication
preference, was comprised of all patients in the safety
sample who had at least one post-baseline outcome
research evaluation (including ASEX). LOCF was the pri-
mary analysis used for the effectiveness research sample
(IAQ, CGI-I, CGI-S), whereas observed cases (OC) was the
primary analysis used for the outcomes research sample
(ASEX).
Analyses
The results from the ASEX evaluation were subject to anal-
ysis of covariance (ANCOVA) with respect to the mean
change from baseline in ASEX Total Score. The ANCOVA
model included treatment group (aripiprazole, SOC) and
gender as main effects, with the baseline score as a covari-
ate. Each additional OC week and each LOCF week was
analysed similarly. For the analysis of LOCF data, country
was also included as a main effect within the model. In
addition, the baseline ASEX Total Score was analysed with
an ANCOVA model including treatment group and gen-
der (and country for the LOCF data set).
The proportions of patients with potentially clinically rel-
evant laboratory test values during the 26-week period
were summarised by treatment group. The proportions of
patients with potentially clinically relevant metabolic
parameters during the 26-week period were analysed
using a Cochran-Mantel-Haenszel test controlling for the
presence or absence of baseline abnormality.
The change from baseline in serum prolactin was analysed
using an ANCOVA model which included treatment
group as main effect and baseline value as the covariate.
Baseline serum prolactin levels were analysed with an
ANCOVA model which included treatment group.
Correlation between changes in prolactin and in ASEX
Total score were calculated in a post-hoc analysis using
Spearman rank-order partial correlation controlling for
antipsychotic taken and gender. The antipsychotic taken
was preferred in this analysis over the treatment group as
the effect on prolactin may be different for each antipsy-
chotic. In another post-hoc analysis, the change from
baseline in ASEX Total score (LOCF) was analysed using
the ANCOVA model as described above, but with on treat-
ment CGI-Improvement added as covariates to assess
whether the ASEX advantage is specific and not the result
of the patients overall improvement. Although such an
analysis may suggest a residual treatment effect on the
ASEX Total Score that can not be attributed to the patient's
global improvement, any analysis that adjusts for post-
randomization covariates must be considered speculative
in nature.
Results
The demographics, primary efficacy results and safety
findings of the STAR study have been presented in detail
elsewhere [18]. This paper will present the results of the
patient-reported secondary endpoint ASEX and the safety
endpoint of serum prolactin levels.
Patient disposition and demographics
A total of 593 patients were enrolled into the study and
555 patients were randomised to receive study treatment
with aripiprazole (n = 284) or SOC (n = 271) for 26
weeks. Of patients randomised to receive SOC, 75
patients received olanzapine, 110 patients received
quetiapine, and 81 patients received risperidone. Five
patients in the SOC group were randomised, but never
received study medication. Table 1 shows the baseline
demographic characteristics of the randomised patient
population including their previous medication. Patient
disposition data are summarised in Table 2.
The most common primary reason for a change in medi-
cation in accordance with the study inclusion criteria were
poorly controlled positive (aripiprazole 32%, SOC 23%)
and negative symptoms (aripiprazole 25%, SOC 32%),
followed by weight gain (aripiprazole 12%, SOC 12%).
The mean daily dose of study medication at the end of the
treatment period was 18.7 mg aripiprazole, 12.5 mg olan-
zapine, 386.8 mg quetiapine, and 4.6 mg risperidone.
Clinical effectiveness and outcomes
Primary efficacy outcomes
The results of the primary effectiveness analysis (IAQ,
GCI-I and CGI-S scores) in the STAR study have been
described in detail elsewhere [18]. However in summaryBMC Psychiatry 2008, 8:95 http://www.biomedcentral.com/1471-244X/8/95
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the aripiprazole treatment group (n = 268) resulted in sig-
nificantly better effectiveness than SOC (n = 254; P <
0.001; week 26 LOCF) as evidenced by the IAQ total score
beginning at the first assessment point (week 4) and this
was sustained through to week 26.
Patient-reported secondary outcome variables: sexual function 
(ASEX)
Both treatment groups experienced improvements in sex-
ual function from baseline as assessed by ASEX; the
improvement was significantly greater in the aripiprazole
group compared with the SOC group (Figure 1). The dif-
ference in favour of aripiprazole was statistically signifi-
cant from Week 8 (first assessment point) onwards. At 26
weeks, the ASEX Total Score had dropped by 1.88 points
from 19.27 at baseline, compared with a drop of 0.92
from 19.7 at baseline in the SOC group (p = 0.032; OC).
Further analyses were performed on each antipsychotic
taken. However, the results of this sub-analysis should be
treated with care as the investigator could determine the
antipsychotic taken in the SOC group. Figure 2 shows the
results for each agent at week 26 (OC data) demonstrating
that of the SOC group quetiapine had a greater improve-
ment on ASEX Total score than olanzapine or risperidone.
At baseline all groups had similar ASEX Total scores.
There was no interaction found between treatment and
gender in the analysis of the ASEX Total Score. However
when pooling the SOC and aripiprazole group, male
Table 1: Baseline demographic characteristics of the randomised patient population [18].
Variable Aripiprazole (N = 284) All SOC (N = 271) Total (N = 555)
Age, years
Mean 38.1 38.8 38.5
Median 36.5 37.0 37.0
SE 10.8 11.1 10.9
Gender, n (%)
Male 169 (59.5) 163 (60.1) 332 (59.8)
Female 115 (40.5) 108 (39.9) 223 (40.2)
Race, n (%)
White 274 (96.5) 262 (96.7) 536 (96.6)
Black 3 (1.1) 1 (0.4) 4 (0.7)
Asian 3 (1.1) 6 (2.2) 9 (1.6)
Other 4 (1.4) 2 (0.7) 6 (1.1)
Weight, kg
Mean 80.4 81.0 80.7
Median 79.0 79.0 79.0
SE 17.5 17.0 17.2
Missing 22
Schizophrenia type, n (%)
Disorganised 24 (8.5) 32 (11.8) 56 (10.1)
Catatonic 3 (1.1) 4 (1.5) 7 (13)
Paranoid 189 (66.5) 172 (63.5) 361 (65.0)
Residual 31 (10.9) 36 (13.3) 67 (12.1)
Undifferentiated 37 (13.0) 27 (10.0) 64 (11.5)
Age at time of first hospitalisation, years
Mean 28.3 28.7 28.5
Median 27.0 27.0 27.0
SE 8.5 8.7 8.6
Missing 35 26 61
Previous medication, N (%)
Any Antipsychotic Medication* 273 (96.1) 267 (98.5) 540 (97.3)
Olanzapine 75 (26.4) 85 (31.4) 160 (28.8)
Quetiapine 15 (5.3) 17 (6.3) 32 (5.8)
Risperidone 66 (23.2) 69 (25.5) 135 (24.3)
* The remaining patients not accounted for by olanzapine, quetiapine and risperidone received a range of antipsychotic medication including 
amisulpride, benperidol, bromperidol, chlorpromazine, chlorprothixene, clozapine, cyamemazine, flupenthixol, fluphenazine, haloperidol, loxapine, 
melperone, methotrimeprazine, perazine, periciazine, perphenazine, pipamperone, pipothiazine, sertindole, sulpiride, thioridazine, trifluoperazine, 
ziprasidone, zotepine, zuclopenthixolBMC Psychiatry 2008, 8:95 http://www.biomedcentral.com/1471-244X/8/95
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patients exhibited an improvement in ASEX Total score of
-1.53 (SE 0.31) from a baseline score of 17.93 compared
to an improvement of -0.71 (SE 0.41) in the female
patients (baseline score 21.90), suggesting that for the
male patients sexual dysfunction was more affected by a
change of medication.
In a post-hoc analysis, the change from baseline in ASEX
Total Score was also adjusted for CGI-I, and a statistically
significant treatment difference was still observed (-1.47
for aripiprazole versus -0.67; p = 0.024).
Safety
Adverse events
The results of the safety analysis have been reported in
detail elsewhere [18]. In summary, the incidence of treat-
ment-emergent AEs was similar in both treatment groups
(77% in the aripiprazole group versus 71% in the SOC
group). The most common AEs (≥ 10%) were insomnia,
anxiety, headache, and nausea in the aripiprazole group,
and anxiety and somnolence in the SOC group.
Serum prolactin levels
Baseline mean serum prolactin levels were similar in the
two treatment groups (43.4 mg/dL in the aripiprazole
group and 42.3 mg/dL in the SOC group, p = NS). At week
26, mean decreases in serum prolactin were 34.2 mg/dL in
the aripiprazole group, compared with 13.3 mg/dL in the
SOC group (p < 0.001; OC) (Figure 3). The maximum on-
treatment effect on serum prolactin levels in the safety
sample was a mean reduction of 28.8 mg/dL in the arip-
iprazole, versus a mean increase of 0.3 mg/dL in the SOC
group (p < 0.001).
Potentially clinically relevant elevations in prolactin levels
during the 26-week period were seen in a significantly
higher proportion of patients in the SOC group (136
patients [54.4%]) compared with the aripiprazole group
(45 patients [16.8%]).
When interpreting the results of these sub analyses, it
should be considered that the investigators could choose
the antipsychotic treatment in the SOC group. As can be
seen in figure 4, the patients treated with aripiprazole,
olanzapine and quetiapine showed a mean decrease in
serum prolactin levels whereas patients treated with risp-
eridone showed a mean increase in serum prolactin at
week 26.
No interaction between treatment and sex was seen but
male patients had a greater mean decrease in prolactin at
week 26 compared with the female patients (22.67 mg/dL
SE 2.15 vs 8.95 mg/dL SE 2.61, respectively).
Correlation between changes from baseline in ASEX Total Score and 
Serum prolactin levels
There was no meaningful correlation found between the
changes from baseline in ASEX Total Score and prolactin
(r = 0.12, p = 0.036). Moreover, further inspection of the
data revealed some influential outliers. When the two out-
lying observations were removed from the analyses, it
resulted in a loss of statistical significance.
Discussion
The STAR study was designed to allow comparison of arip-
iprazole with SOC treatment in a setting close to daily
clinical practice, and also to assess the patient and car-
egiver perspective on the treatment received. The primary
outcome measure in the STAR study was the IAQ total
score, which takes into account both the efficacy and tol-
erability of an antipsychotic medication and thus is a
measure of effectiveness rather than merely efficacy [21].
The results of STAR demonstrated clearly that at all time
points, treatment with aripiprazole was associated with
Table 2: Summary of patient disposition [18].
Patient Status Number of patients (%)
Aripiprazole All SOC Total
Enrolled 593
Randomised 284 271 555
Discontinuation from treatment phase 120 (42.3) 105 (38.7) 225 (40.5)
Lack of efficacy 33 (11.6) 20 (7.4) 53 (9.5)
Adverse event 57 (20.1) 43 (15.9) 100 (18.0)
Withdrew consent 8 (2.8) 18 (6.6) 26 (4.7)
Death 1 (0.4) 2 (0.7) 3 (0.5)
Lost to follow-up 6 (2.1) 6 (2.2) 12 (2.2)
Poor or non-compliance 10 (3.5) 10 (3.7) 20 (3.6)
Pregnancy 2 (0.7) 2 (0.7) 4 (0.7)
Non longer meets study criteria 2 (0.7) 3 (1.1) 5 (0.9)
Other 1 (0.4) 1 (0.4) 2 (0.4)
Completed treatment phase 164 (57.7) 166 (61.3) 330 (59.5)
Randomised, but did not receive study medication 2 5 7BMC Psychiatry 2008, 8:95 http://www.biomedcentral.com/1471-244X/8/95
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significantly better effectiveness compared with SOC
treatment, in the form of one of three atypical agents cho-
sen by the clinician as optimal treatment for the individ-
ual patient.
The results of the ASEX evaluation in the STAR study
showed that patients treated with aripiprazole experi-
enced significantly less sexual dysfunction at the end of
the treatment period compared with patients receiving
SOC. These findings are consistent with the existing body
of evidence for atypical antipsychotics, as discussed
below. When considering the agents within the SOC
group individually, olanzapine and quetiapine were asso-
ciated with less sexual dysfunction at the end of treatment
and risperidone was associated with the least improve-
ment in sexual dysfunction, which is in agreement with
the Intercontinental Schizophrenia Outpatient Health
Outcomes IC-SOHO study [13].
Whilst sexual dysfunction has traditionally run the risk of
being underestimated in clinical trials due to the lack of
self-reporting and unwillingness to discuss the issue, there
is increasing awareness amongst clinicians and allied
mental health care professionals that sexual dysfunction is
a common and distressing side effect of antipsychotic
medication [22]. A survey carried out by the UK patient
advocacy group Rethink (formerly the National Schizo-
phrenia Fellowship) showed that 66% of patients who
had experienced sexual dysfunction felt that this side
effect was 'bad' or 'very bad' [23]. Men appear to suffer
more than women [22]. However, in this study female
patients showed less improvement in sexual function
Mean change from baseline in ASEX Total score (OC) Figure 1
Mean change from baseline in ASEX Total score (OC).
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than their male counterparts who experienced greater
improvement in ASEX score. There is evidence that silde-
nafil is able to address such antipsychotic related sexual
dysfunction in men including those patients who also
report raised serum prolactin levels. In the study by
Gopalakrishnan et al, [4] 77% reported improved erec-
tions and 74% (24 patients) felt they would use the med-
ication in future compared with 26% of the placebo
group. However, it may be possible to improve sexual dys-
function in both male and female by changing antipsy-
chotic medication rather than adding further medication
to the treatment regimen of schizophrenia patients.
Overall, around half of all patients treated with antipsy-
chotics experience sexual dysfunction; the associated dis-
tress and frustration may have a profound effect on the
quality of life of the patient as well as making personal
relationships more difficult, and sexual dysfunction may
lead to non-compliance with the antipsychotic treatment
regimen [24-26]. In fact, if considering QLS the aripipra-
zole group reported a greater increase in total QLS and in
QLS related to interpersonal relations (table 3) compared
to the SOC group. This may be in part related to the
greater improvement in ASEX score also observed in these
patients.
Prolactin plays a key role in the regulation of sexual
behaviour and activity [27], and elevated serum prolactin
levels associated with antipsychotic medication are
known to cause erectile dysfunction, orgasmic difficulties,
amenorrhoea and gynaecomastia [11,28]. The serum pro-
lactin measurements also demonstrated that patients in
the aripiprazole treated group were more likely to have
normal serum prolactin levels at the end of the treatment
period compared with patients receiving SOC. Given pre-
vious risperidone data, it is not surprising that this was the
only agent in the SOC treatment group associated with an
increase in mean serum prolactin level at week 26.
The implications of sexual dysfunction for treatment com-
pliance and the prevention of relapse, together with the
potential link between primary and secondary prolacti-
naemia and breast cancer and/or decreased bone mineral
density [29] makes serum prolactin an important end-
point in the assessment of antipsychotic therapy. A grow-
ing evidence base indicates that, with the exception of
risperidone, the atypical antipsychotics are less associated
with hyperprolactinaemia than conventional antipsychot-
ics. Some agents, including quetiapine, olanzapine and
clozapine, were shown previously to cause no significant
or sustained increase in serum prolactin in adult patients
[6-10]. More recently, a systematic review of short-term
clinical trials with aripiprazole showed that the effect of
aripiprazole on serum prolactin levels was comparable to
that of placebo, and significantly lower than that of risp-
eridone [14]. The IC-SOHO study demonstrated that a
reduction in the incidence of elevated serum prolactin
translates to a reduced potential for sexual side effects
[13]. Switching patients from conventional antipsychotics
or risperidone to an antipsychotic with less potential for
prolactin elevation is therefore likely to be an effective
measure for improving treatment compliance and reduc-
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ing the risk of symptomatic relapse in patients experienc-
ing sexual dysfunction during antipsychotic therapy.
One major limitation to the interpretation of the findings
is that the STAR study employed an open-label design and
both patients and physicians would have been aware as to
whether they were receiving study medication or not.
Moreover, physicians could choose the SOC medication.
This may have introduced bias in subjective measures
such as the ASEX, and caution should thus be exercised
when interpreting these results.
Conclusion
In conclusion, the results of this study show that treat-
ment with aripiprazole has the potential to improve not
only the clinical effectiveness, but also to reduce the
potential for sexual dysfunction, which is increasingly
held to be one of the most distressing side effects associ-
ated with antipsychotic treatment, as well as the risk of
severe side effects associated with hyperprolactinaemia
such as loss of bone mineral density and osteoporosis. It
is important that a holistic approach is taken to the man-
agement of schizophrenia to improve patients' quality of
life and potentially compliance.
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